News of the day:
In pts [patients] with PRC, XL-880 demonstrated antitumor activity
| Name | Target | Company | Phase |
| AZD-2171 | Vegf c-Kit Pdgfr-β | AstraZeneca | ph2 |
| AZD-2171 | Vegf c-Kit Pdgfr-β | AstraZeneca | ph2 |
| PD-325901 | Mek | Pfizer | ph2 |
| XL-647 | ErbB1,2 Vegfr-2 | Exelixis | ph2 |
| XL-880 | c-Met Vegf | Exelixis | ph2 |
| ARQ-197 | c-Met | Arqule | ph1 |
| BAY-579352 | Vegfr-2,3 c-Kit Pdgfr-β | Bayer | ph1 |
| BAY-734506 | c-Kit Ret Pdgfr Raf | Bayer | ph1 |
| BIBW-2992 | ErbB (irrev) | BI | ph1 |
| PD-325901 | Mek | Pfizer | ph1 |
| PF-299804 | ErbB (irrev) | Pfizer | ph1 |
| Ticribine | Akt | VioQuest | ph1 |
| XL-647 | ErbB 1,2 Vegfr-2 | Exelixis | ph1 |
| XL-820 | Vegfr c-Kit Pdgfr | Exelixis | ph1 |
| XL-880 | c-Met Vegf | Exelixis | ph1 |
| ARRY-543 | ErbB1, 2 | Array | ph1 |
| AT-13148 | Akt Rock PKA | Astex | |
| AV-951 | Vegf | Aveo | ph1 |
| BAY-734506 | c-Kit Ret Pdgfr Raf | Bayer | |
| BMS-698769 | c-Met | BMS | |
| CEP-11981 | Tie2 Vegfr | Cephalon | |
| CUDC-101 | HDAC / ErbB | Curis | |
| NVP-BEZ235 | Pi3k | Novartis | |
| OSI-906 | IGF-1R | Osi | |
| RDEA-119 | Mek | Ardea | |
| SGX-523 | c-Met | SGX | |
| SR-13654 | Src | SRI | |
| XL-765 | Pi3k, mTOR | Exelixis | |
| XL-820 | c-Kit | Exelixis | |
| XL-844 | Chk1, 2 | Exelixis | |
| ZD-6474 | Vegfr-2 EGFR | ||
| ZM 447439 | Aurora | ||
| CRT-59359 | PKD | CRT |
